Review of biphasic insulin aspart in the treatment of type 1 and 2 diabetes

References

• American Diabetes AssociationStandards of medical care in diabetes–2007Diabetes Care200730S44117192377
   PubMedGoogle Scholar
• AbrahamianHLudvikBSchernthanerGImprovement of glucose tolerance in type 2 diabetic patients: traditional vs modern insulin regimens (results from the Austrian Biaspart Study)Horm Metab Rex2005376849
   PubMed Web of Science ®Google Scholar
• BlondeLCurrent challenges in diabetes managementClin Cornerstone20057Suppl 3S61716545737
   PubMedGoogle Scholar
• BoehmBOHomePDBehrendCPremixed insulin aspart 30 vs premixed human insulin 30/70 twice daily: A randomized trial in type 1 and type 2 diabetic patientsDiabet Med200219393912027927
   PubMed Web of Science ®Google Scholar
• BoehmBOVazJABrondstedLLong-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetesEur J Intern Med20041549650215668084
   PubMedGoogle Scholar
• CDC: National Diabetes Fact Sheet2005 Accessed 10 April 2007. URL: http://www.cdc.gov/diabetes/pubs/factsheet05.htm
   Google Scholar
• ChenJWFrystykJLauritzenTImpact of insulin antibodies on insulin aspart pharmacokinetics and pharmacodynamics after 12-week treatment with multiple daily injections of biphasic insulin aspart 30 in patients with type 1 diabetesEur J Endocrinol20051539071316322398
   PubMed Web of Science ®Google Scholar
• ChenJWLauritzenTBojesenAMultiple mealtime administration of biphasic insulin aspart 30 versus traditional basal-bolus human insulin treatment in patients with type 1 diabetesDiabetes Obes Metab20068682917026493
   PubMed Web of Science ®Google Scholar
• ChristiansenJSVazJAMetelkoZTwice daily biphasic insulin aspart improves postprandial glycemic control more effectively than twice daily NPH insulin, with low risk of hypoglycemia, in patients with type 2 diabetesDiabetes Obes Metab200354465414617231
   PubMed Web of Science ®Google Scholar
• DanemanDType 1 diabetesLancet20063678475816530579
   PubMed Web of Science ®Google Scholar
• DavidsonJVexiauPCucinottaDVazJBiphasic insulin aspart 30: literature review of adverse events associated with treatmentClin Ther200527Suppl 2S758816519039
   PubMedGoogle Scholar
• DCCT (Diabetes Control and Complications Trial)/Epidemiology of Diabetes Interventions and Complications Research GroupRetinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapyN Engl J Med2000342381910666428
   PubMed Web of Science ®Google Scholar
• DECODE Study Group, European Diabetes Epidemiology GroupIs the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?Diabetes Care2003266889612610023
   PubMed Web of Science ®Google Scholar
• GarberAJPremixed insulin analogues for the treatment of diabetes mellitusDrugs200666314916398567
   PubMed Web of Science ®Google Scholar
• GarberAJWahlenJWahlTAttainment of glycaemic goals in type 2 diabetes with once-, twice-or thrice-, daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study)Diabetes Obes Metab20068586616367883
   PubMed Web of Science ®Google Scholar
• HalimiSRaskinPLieblAEfficacy of biphasic insulin aspart in patients with type 2 diabetesClin Ther200527S577416519038
   PubMed Web of Science ®Google Scholar
• HendersonJNAllenKVDearyIJHypoglycemia in insulin-treated type 2 diabetes: frequency, symptoms and impaired awarenessDiabet Med20032010162114632703
   PubMed Web of Science ®Google Scholar
• HermansenKColomboMStorgarrdHImproved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetesDiabetes Care200225883811978685
   PubMed Web of Science ®Google Scholar
• HermansenKVaalerSMadsbadSPostprandial glycemic control with biphasic insulin aspart in patients with type 1 diabetesMetabolism20025189690012077738
   PubMed Web of Science ®Google Scholar
• HomePDBarriocanalLLindholmAComparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteersEur J Clin Pharmacol19995519920310379635
   PubMed Web of Science ®Google Scholar
• International Diabetes FederationDiabetes Atlas20073 Accessed 10 April 2007. URL: http://www.eatlas.idf.org/media
   Google Scholar
• IDF Clinical Guidelines Task ForceGlobal guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal careDiabet Med2006235799316759299
   PubMed Web of Science ®Google Scholar
• IwamotoYA randomized, multcentre trial of biphasic insulin aspart versus biphasic human insulin in type 2 diabetesDiabetologia200346Suppl 2A270
   Google Scholar
• JacobsenLVSogaardBRiisAPharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspartEur J Clin Pharmacol20005639940311009049
   PubMed Web of Science ®Google Scholar
• JainRWahlTWahlenJPatients with type 2 diabetes can achieve A1c targets with once-daily biphasic insulin aspart 70/30 (NovoLog Mix 70/30) before supperDiabetes200453Suppl2A130
   Google Scholar
• JohnsonJAPoharSLMajumdarSRHealth care use and costs in the decade after identification of type 1 and type 2 diabetes: a population-based studyDiabetes Care2006292403817065675
   PubMedGoogle Scholar
• KannPHWascherTZackovaVStarting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimeprideExp Clin Endocrinol Diabetes20061145273217115351
   PubMed Web of Science ®Google Scholar
• KapitzaCRaveKOstrowskiKReduced postprandial glycaemic excursion with biphasic insulin aspart 30 injected immediately before a mealDiabet Med200421500115089801
   PubMed Web of Science ®Google Scholar
• KiloCMezitisNJainRStarting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metforminJ Diabetes Complications2003173071314583174
   PubMed Web of Science ®Google Scholar
• KoroCEBowlinSJBourgeoisNGlycemic control from 1988–2000 among US adults diagnosed with type 2 diabetes: a preliminary reportDiabetes Care200427172014693960
   PubMed Web of Science ®Google Scholar
• KorytkowskiMNiskanenLAsakuraTFlexPen®: Addressing issues of confidence and convenience in insulin deliveryClin Ther200527S8910016519040
   PubMed Web of Science ®Google Scholar
• KvapilMSwatkoAHilbergCBiphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetesDiabetes Obes Metab20068394816367881
   PubMed Web of Science ®Google Scholar
• LandgrafRThe relationship of postprandial glucose to HbA1cDiabetes Metab Res Rec200420Suppl 2S912
   PubMedGoogle Scholar
• LebovitzHEAustinMMBlondeLACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendationsEndocr Pract200612Suppl161216627372
   PubMedGoogle Scholar
• LeiterLACerielloADavidsonJAInternational Prandial Glucose Regulation (PGR) Study Group. Postprandial glucose regulation: New data and new implicationsClin Ther200527S425616519037
   PubMed Web of Science ®Google Scholar
• LigthelmRJMouritzenULynggaardHBiphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomized open-label parallel group four months comparison in patients with type 2 diabetesExp Clin Endocrinol Diabetes2006114511917115349
   PubMed Web of Science ®Google Scholar
• LindholmAJensenLBHomePDImmune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetesDiabetes Care2002258768211978684
   PubMed Web of Science ®Google Scholar
• McSorleyPTBellPMJacobsenLVTwice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double–blind crossover study in adults with type 2 diabetes mellitusClin Ther200224530912017398
   PubMed Web of Science ®Google Scholar
• MonnierLLapinskiHColetteCContributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetes: Variations with increasing levels of HbA1cDiabetes Care200326881512610053
   PubMed Web of Science ®Google Scholar
• MortensenHKocovaMTengLYBiphasic insulin aspart vs human insulin in adolescents with type 1 diabetes on multiple daily insulin injectionsPediatr Diabetes2006713
   Web of Science ®Google Scholar
• MudaliarSEdelmanSVInsulin therapy in type 2 diabetesEndocrinol Metab Clin North Am2001309358211727406
   PubMed Web of Science ®Google Scholar
• NathanDMClearyPABacklundJYDCCTIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetesN Engl J Med200535326435316371630
   PubMed Web of Science ®Google Scholar
• NauckMADuranSKimDA comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority studyDiabetologia2007502596717160407
   PubMed Web of Science ®Google Scholar
• NiskanenLJensenLERastamJRandomized, multinational open-label, 2-period crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitusClin Ther2004265314015189750
   PubMed Web of Science ®Google Scholar
• NolanJJO’HalloranDMcKennaTJThe cost of treating type 2 diabetes (CODEIRE)Ir Med J20061003071017274175
   PubMedGoogle Scholar
• Provider Synergies LLCHypoglycemicsInsulins Review2006
   Google Scholar
• RaskinPRAllenEHollanderPInitiating insulin therapy in type 2 diabetesDiabetes Care200528260515677776
   PubMed Web of Science ®Google Scholar
• RaskinPRHollanderPALewinAon behalf of the INITIATE Study GroupBasal insulin or premix analogue therapy in type 2 diabetes patientsEur J Intern Med200718566217223044
   PubMed Web of Science ®Google Scholar
• RayJAValentineWJRozeSInsulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs insulin glargine in the USDiabetes Obes Metab200791031317199725
   PubMed Web of Science ®Google Scholar
• RazIStranksSFilipczakREfficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label studyClin Ther20052714324316291416
   PubMed Web of Science ®Google Scholar
• RiddLeMCRosenstockJGerichJfor the Insulin Glargine 4002 Study InvestigatorsThe treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patientsDiabetes Care2003263080614578243
   PubMed Web of Science ®Google Scholar
• RollaARRakelREPractical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analoguesClin Ther20052711132516199240
   PubMed Web of Science ®Google Scholar
• SchmoelzerIde CampoAPresslHBiphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with Type 2 diabetesExp Clin Endocrinol Diabetes20051131768115789278
   PubMed Web of Science ®Google Scholar
• SicatBLMorganLANew therapeutic options for the management of diabetesConsult Pharm200722455617367252
   PubMedGoogle Scholar
• StumvollMGoldsteinBJvan HaeftenTWType 2 diabetes: principles of pathogenesis and therapyLancet200536513334615823385
   PubMed Web of Science ®Google Scholar
• Temelkova-KurktschievTSKoehlerCHenkelEPostchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c levelDiabetes Care2000231830411128361
   PubMed Web of Science ®Google Scholar
• TibaldiJRakelREWhy, when and how to initiate insulin therapy in patients with type 2 diabetesInt J Clin Pract2007616334417394436
   PubMed Web of Science ®Google Scholar
• ValentineWJPalmerAJLammertMLong-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients; cost-effectiveness analysis in the UK settingCurr Med Res Opin20052120637116368057
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) GroupIntensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)Lancet1998352837539742976
   PubMed Web of Science ®Google Scholar
• WildSRoglicGGreenAGlobal prevalence of diabetes: estimates for the year 2000 and projections for 2030Diabetes Care20042710475315111519
   PubMed Web of Science ®Google Scholar